Malaysia NPRA Updates Drug Registration Guidance Document (DRGD) with Revised Variation Timelines and Reliance Pathway

The National Pharmaceutical Regulatory Authority (NPRA), under the Ministry of Health Malaysia, issued an update to the Drug Registration Guidance Document (DRGD) on 15 January 2026. The update revises processing timelines for variations of registered pharmaceutical products and introduces a reliance mechanism for pharmaceutical products approved by recognized reference regulatory authorities, strengthening the product registration and variation assessment process.

These changes were approved by the Product Evaluation Committee (JKPP) following WHO Benchmarking activities to reduce assessment duplication, improve transparency, and align Malaysia’s regulatory framework with international best practices. Product Registration Holders must comply with the new application procedures and timelines, which replace existing provisions in the Malaysian Variation Guidelines, while continuing to ensure quality and safety, efficacy, and compliance with Drug Master File (DMF) requirements.